Ameriprise Financial Inc. Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Ameriprise Financial Inc. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 971,133 shares of the medical research company’s stock after acquiring an additional 14,004 shares during the period. Ameriprise Financial Inc. owned 0.54% of IQVIA worth $190,838,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of IQV. Synergy Asset Management LLC acquired a new position in IQVIA in the fourth quarter valued at $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA in the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter valued at approximately $44,000. Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in shares of IQVIA in the 4th quarter valued at approximately $60,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on IQV shares. Citigroup cut their price target on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, UBS Group dropped their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $237.62.

IQVIA Stock Down 4.1 %

IQV stock opened at $146.12 on Wednesday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company’s 50 day simple moving average is $165.94 and its 200-day simple moving average is $189.86. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The firm has a market capitalization of $25.76 billion, a PE ratio of 19.48, a P/E/G ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.